Beta cell function and global glucose metabolism are impaired in Dp(16)1Yey mouse model of Down syndrome

Down syndrome (DS) or trisomy 21 is the most prevalent genetic disorder in the world. In addition to common symptoms such as intellectual disabilities and morphological abnormalities, several comorbidities are associated with DS, including metabolic dysfunction. Obesity and diabetes are more prevalent in people with DS compared with the general population. However, the mechanisms linking obesity/diabetes to DS remain poorly understood. Systematic investigation of metabolic disorders in animal models of DS is scarce.

• Publication year

  2025

• Venue

  Diabetes, obesity and metabolism

• Publication date

  2025-01-13

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/dom.16155PMID 39803786
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Exploring the link between hedonic overeating and prefrontal cortex dysfunction in the Ts65Dn trisomic mouse model

  2023influential reference
• Lithium treatment mitigates the diabetogenic effects of chronic cortico-therapy.

  2023cited by this paper
• Dysregulated systemic metabolism in a Down syndrome mouse model

  2022influential reference
• Sex differences in the molecular programs of pancreatic cells contribute to the differential risks of type 2 diabetes.

  2022cited by this paper
• Diabetes and Obesity in Down Syndrome Across the Lifespan: A Retrospective Cohort Study Using U.K. Electronic Health Records

  2022cited by this paper
• Type 2 Diabetes Mellitus and Alzheimer’s Disease: Shared Molecular Mechanisms and Potential Common Therapeutic Targets

  2022cited by this paper
• Sex-biased islet β cell dysfunction is caused by the MODY MAFA S64F variant by inducing premature aging and senescence in males

  2021cited by this paper
• Metabolic Diseases and Down Syndrome: How Are They Linked Together?

  2021cited by this paper
• DYRK1A Inhibitors as Potential Therapeutics for β-Cell Regeneration for Diabetes.

  2021cited by this paper
• A natural DYRK1A inhibitor as a potential stimulator for β‐cell proliferation in diabetes

  2021cited by this paper
• Coat Color-Facilitated Efficient Generation and Analysis of a Mouse Model of Down Syndrome Triplicated for All Human Chromosome 21 Orthologous Regions

  2021cited by this paper
• Children with Gastroesophageal Reflux Disease Consume more Calories and Fat Compared to Controls of Same Weight and Age.

  2020cited by this paper
• Sex differences in metabolic regulation and diabetes susceptibility

  2019cited by this paper
• Trends in Obesity and Overweight in Oregon Children With Down Syndrome

  2019cited by this paper
• Pharmacologic and genetic approaches define human pancreatic beta cell mitogenic targets of DYRK1A inhibitors.

  2019cited by this paper
• Corrigendum to "Increased levels of inflammatory plasma markers and obesity risk in a mouse model of Down syndrome" [Free Radic. Biol. Med. 114 (2018) 122-130].

  2018cited by this paper
• Increased levels of inflammatory plasma markers and obesity risk in a mouse model of Down syndrome

  2018cited by this paper
• Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity.

  2018cited by this paper
• Lifespan analysis of brain development, gene expression and behavioral phenotypes in the Ts1Cje, Ts65Dn and Dp(16)1/Yey mouse models of Down syndrome

  2018cited by this paper
• A single extra copy of Down syndrome critical region 1–4 results in impaired hepatic glucose homeostasis

  2018cited by this paper
• Characterization of Thyroid Abnormalities in a Large Cohort of Children with Down Syndrome


  2017cited by this paper
• Association between Physical Activity and Adiposity in Adolescents with Down Syndrome

  2017cited by this paper
• Gender differences in glucose homeostasis and diabetes.

  2017cited by this paper
• Rodent models in Down syndrome research: impact and future opportunities

  2017cited by this paper
• β‐Cell dysfunction in diabetes: a crisis of identity?

  2016cited by this paper
• Inhibition of DYRK1A and GSK3B induces human β-cell proliferation

  2015cited by this paper
• Increased expression of the glucose-responsive gene, RCAN1, causes hypoinsulinemia, β-cell dysfunction, and diabetes.

  2012cited by this paper
• Reduced exercise capacity in persons with Down syndrome: cause, effect, and management

  2010cited by this paper
• Prevalence of overweight and obesity in Down's syndrome and other mentally handicapped adults living in the community.

  2008cited by this paper
• Duplication of the entire 22.9 Mb human chromosome 21 syntenic region on mouse chromosome 16 causes cardiovascular and gastrointestinal abnormalities.

  2007cited by this paper
• Early administration of keratinocyte growth factor improves {beta}-cell regeneration in rat with streptozotocin-induced diabetes.

  2007cited by this paper
• Calcineurin/NFAT signalling regulates pancreatic beta-cell growth and function.

  2006cited by this paper
• Increased prevalence of Down’s syndrome in individuals with type 1 diabetes in Denmark: a nationwide population-based study

  2006cited by this paper
• National estimates and race/ethnic-specific variation of selected birth defects in the United States, 1999-2001.

  2006cited by this paper
• Calcineurin/NFAT signalling regulates pancreatic β-cell growth and function

  2006cited by this paper
• ERK1/2-dependent Activation of Transcription Factors Required for Acute and Chronic Effects of Glucose on the Insulin Gene Promoter*

  2005cited by this paper
• Correlates of specific childhood feeding problems

  2003cited by this paper
• NFAT regulates insulin gene promoter activity in response to synergistic pathways induced by glucose and glucagon-like peptide-1.

  2002cited by this paper
• Prevalence of coeliac disease in Down's syndrome

  2001cited by this paper
• Type 1 diabetes mellitus and Down's syndrome: prevalence, management and diabetic complications

  1998cited by this paper
• Insulin Administration Enhances Growth of the β-Cell Mass in Streptozotocin-Treated Newborn Rats

  1997cited by this paper
• Early-onset diabetes in the general and the Down's syndrome population.

  1969cited by this paper

• Gene dosage imbalance disrupts systemic metabolism in the Dp16 Down syndrome mouse model

  2026cites this paper
• Advances in Down Syndrome

  2026cites this paper